KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) EBIT Margin (2018 - 2025)

Historic EBIT Margin for Aurinia Pharmaceuticals (AUPH) over the last 9 years, with Q3 2025 value amounting to 40.49%.

  • Aurinia Pharmaceuticals' EBIT Margin rose 231500.0% to 40.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 26.34%, marking a year-over-year increase of 411700.0%. This contributed to the annual value of 1.99% for FY2024, which is 502500.0% up from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its EBIT Margin stood at 40.49% for Q3 2025, which was up 231500.0% from 28.69% recorded in Q2 2025.
  • Aurinia Pharmaceuticals' EBIT Margin's 5-year high stood at 40.49% during Q3 2025, with a 5-year trough of 5529.87% in Q1 2021.
  • Moreover, its 5-year median value for EBIT Margin was 38.97% (2023), whereas its average is 382.87%.
  • Per our database at Business Quant, Aurinia Pharmaceuticals' EBIT Margin soared by 1455704800bps in 2021 and then crashed by -128000bps in 2023.
  • Over the past 5 years, Aurinia Pharmaceuticals' EBIT Margin (Quarter) stood at 139.74% in 2021, then rose by 29bps to 98.82% in 2022, then skyrocketed by 33bps to 65.8% in 2023, then surged by 96bps to 2.79% in 2024, then surged by 1552bps to 40.49% in 2025.
  • Its EBIT Margin was 40.49% in Q3 2025, compared to 28.69% in Q2 2025 and 34.97% in Q1 2025.